EcoDrugPlus

Neuromedin-K Receptor-Like

Ensembl ID : ENSMAMG00000016578
Gene Symbol: LOC113127798
3 Cross references
218 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-2-Like

Ensembl ID : ENSMAMG00000008298
Gene Symbol: LOC113145494
2 Cross references
193 Possible Orthologues:

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSMAMG00000009070
Gene Symbol: NPY2RL
3 Cross references
176 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSMAMG00000016571
Gene Symbol: NTSR1
3 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSMAMG00000001925
Gene Symbol: NTRK2
1 Cross references
207 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSMAMG00000006607
Gene Symbol: NTRK3
3 Cross references
192 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSMAMG00000010588
Gene Symbol: NTRK1
3 Cross references
199 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSMAMG00000016939
Gene Symbol: NTRK2B
3 Cross references
207 Possible Orthologues:

Nicastrin

Ensembl ID : ENSMAMG00000008544
Gene Symbol: NCSTN
3 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSMAMG00000009259
Gene Symbol: NAMPT
3 Cross references
225 Possible Orthologues:

Nischarin

Ensembl ID : ENSMAMG00000000729
Gene Symbol: NISCH
2 Cross references
208 Possible Orthologues:

Nociceptin Receptor-Like

Ensembl ID : ENSMAMG00000006921
Gene Symbol: LOC113145915
2 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).